Expense

Federal Home Loan Bank of Des Moines Announces 2023 Fourth Quarter and Annual Results, Declares Dividend

Retrieved on: 
Friday, February 16, 2024
Expense, Federal Home Loan Banks, Investment, Bank, Growth, AHP, Organization, Capital, Housing, Asset

In addition, the Bank increased its activity stock requirement on advances from 4.00 percent to 4.50 percent.

Key Points: 
  • In addition, the Bank increased its activity stock requirement on advances from 4.00 percent to 4.50 percent.
  • The Board of Directors approved a fourth quarter 2023 dividend to be paid at an annualized rate of 9.00 percent on average activity-based stock, an increase of 0.50 percent from the prior quarter, and 3.55 percent on average membership stock, an increase of 0.55 percent from the prior quarter.
  • Dividend payments totaling $136 million are expected to be paid on February 23, 2024.
  • Net Income - The Bank recorded net income of $962 million in 2023 compared to $430 million in the prior year.

YieldMax™ ETFs Announces Monthly Distributions on Fund of Funds ETFs

Retrieved on: 
Wednesday, February 14, 2024
TRUST, Prospectus, Investment, Expense, NAV, ETF, Risk, History, Fund, Lovell Minnick Partners, Capital gain, Security, YMAX, Financial adviser

“Acquired Fund Fees and Expenses” are indirect fees and expenses that the Fund incurs from investing in the shares of other investment companies, namely other YieldMax™ ETFs.

Key Points: 
  • “Acquired Fund Fees and Expenses” are indirect fees and expenses that the Fund incurs from investing in the shares of other investment companies, namely other YieldMax™ ETFs.
  • The Distribution Rate and 30-Day SEC Yield are not indicative of future distributions, if any, on the ETFs.
  • Distributions for the ETFs (if any) are variable and may vary significantly from month to month and may be zero.
  • The repetitive payment of distributions may significantly erode an Underlying YieldMax™ ETF’s NAV and trading price over time, potentially resulting in notable losses for investors (including the Fund).

CNH Industrial N.V. Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Wednesday, February 14, 2024
Collection, Expense, Share repurchase, Financial services, Capital market, Investment, Table, Nature, CNH, Adjustment, European, GAAP, Industrial, Uncertainty, EPS, Agriculture, CNH Industrial, FX, European Free Trade Association, Bank

CNH is continuing its efforts to improve through-cycle margins with its two previously announced cost reduction programs.

Key Points: 
  • CNH is continuing its efforts to improve through-cycle margins with its two previously announced cost reduction programs.
  • The second program is focused on restructuring SG&A expenses and was announced in conjunction with Q3 2023 earnings.
  • CNH reports quarterly and annual consolidated financial results under U.S. GAAP and EU-IFRS.
  • Adjusted EBIT Margin of Industrial Activities: is computed by dividing Adjusted EBIT of Industrial Activities by Net Sales of Industrial Activities.

PetVivo Reports Third Quarter of Fiscal 2024 Financial Results

Retrieved on: 
Monday, February 12, 2024
Conference call, Expense, EDINA, Marketing, Average cost, Animal, Sale, MWI, Nine Months, Webcast, Three Months, Research, Cryptocurrency

EDINA, MN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended December 31, 2023 (“third quarter of 2024”).

Key Points: 
  • Conference call begins at 4:00 p.m. Central time today
    EDINA, MN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended December 31, 2023 (“third quarter of 2024”).
  • “We are excited about the progress the Company has made this past quarter, including the addition of Covetrus North America, LLC.
  • (Covetrus), to distribute our products beginning in January 2024,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc.
  • Cost of sales were $183,087 and $223,687 for the three months ended December 31, 2023 and 2022, respectively.

Corporate Plastic Power: Latest Upgraded Points Survey Examines How Employees Actually Use Their Company Credit Cards

Retrieved on: 
Tuesday, January 30, 2024
Transport, Expense, Organization, Reward, Meal, Research, Travel, Cryptocurrency

AUSTIN, Texas, Jan. 30, 2024 /PRNewswire/ -- Upgraded Points recently revealed its latest research findings with a fascinating glimpse into the topic of employees' use of company-issued credit cards. The study identifies the role, usage, and challenges these cards present in a modern workplace.

Key Points: 
  • AUSTIN, Texas, Jan. 30, 2024 /PRNewswire/ -- Upgraded Points recently revealed its latest research findings with a fascinating glimpse into the topic of employees' use of company-issued credit cards.
  • "Our mission was to shed light on how these cards are used, and sometimes, misused," shared Keri Stooksbury, editor-in-chief at Upgraded Points.
  • Upgraded Points surveyed 500 American employees with company-issued credit cards during a week in December 2023.
  • The survey explored card users' purchasing habits, security measures, and personal card usage and asked questions about corporate card misuse.

Sterling Bancorp Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, January 24, 2024
Banking, Professional Services, Finance, F.S.B, Income tax, Sterling Bancorp, Policy, Bank, Treasury, Expense, Trust, Insurance, Recovery, Currency, Comptroller, Government, SBT, Sterling, DOJ, Sterling Bank, Sale, Environment, Plea, Tax, Investment, Federal Home Loan Banks, NOW, Webcast, Cryptocurrency

(the “Bank”), today reported its financial results for the quarter and year ended December 31, 2023.

Key Points: 
  • (the “Bank”), today reported its financial results for the quarter and year ended December 31, 2023.
  • Recoveries during the fourth and third quarter of 2023 were $64 thousand and $1 thousand, respectively, with no charge offs in either quarter.
  • Net Interest Income and Net Interest Margin – Net interest income for the fourth quarter of 2023 was $15.1 million compared to $16.0 million for the prior quarter of 2023 and $18.5 million for the fourth quarter of 2022.
  • Non-Interest Income – Non-interest income for the fourth quarter of 2023 was $0.2 million compared to $0.4 million for the prior quarter and $0.2 million for the fourth quarter of 2022.

The North West Company Inc. Announces Third Quarter Earnings and a Quarterly Dividend

Retrieved on: 
Wednesday, December 6, 2023
Depreciation, Alaska Permanent Fund, Interest, The Company, NWC, Expense, TSX, North Star Air, GAAP, Bookkeeping

WINNIPEG, Manitoba, Dec. 06, 2023 (GLOBE NEWSWIRE) -- (TSX: NWC): The North West Company Inc. (the "Company" or "North West") today reported its unaudited financial results for the third quarter ended October 31, 2023.

Key Points: 
  • WINNIPEG, Manitoba, Dec. 06, 2023 (GLOBE NEWSWIRE) -- (TSX: NWC): The North West Company Inc. (the "Company" or "North West") today reported its unaudited financial results for the third quarter ended October 31, 2023.
  • It also announced that the Board of Directors has declared a quarterly dividend of $0.39 to shareholders of record on December 29, 2023, to be paid on January 15, 2024.
  • Higher earnings in North Star Air from an increase in third party cargo and passenger volumes and improved aircraft utilization was also a factor.
  • The Company uses the following non-GAAP financial measures: earnings before interest, income taxes, depreciation and amortization ("EBITDA"), adjusted EBITDA and adjusted net earnings.

PetVivo Reports Second Quarter of Fiscal 2024 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Ethos, Sale, Webcast, Three Months, Research, ThinkEquity, Conference call, Clinical trial, Expense, Patient, Animal, Marketing, Pain, EDINA, Average cost, Quality of life, Limp, Total revenue, Cryptocurrency, Clothing, Pharmaceutical industry, Life insurance, Conference

EDINA, MN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended September 30, 2023 (“second quarter of 2024”).

Key Points: 
  • Conference call begins at 4:00 p.m. Central time today
    EDINA, MN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended September 30, 2023 (“second quarter of 2024”).
  • Revenues were $207,366 and $223,280 for three months ended September 30, 2023 and 2022, respectively.
  • Cost of sales was $140,913 and $148,149 for the three months ended September 30, 2023 and 2022, respectively.
  • The weighted average number of shares outstanding was 12,325,973 and 10,021,090 for the six months ended September 30, 2023 and 2022, respectively.

eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Assistant, PD-L1, Associate, Therapy, Safety, D, RECIST, Fulvestrant, Effector, Expense, Investment, STRI Group, Artificial intelligence, Clinical trial, Breast cancer, Administration, D&O, Patient, PFS, Research, Science, Pembrolizumab, FA, KICKSTART, G&A, Messenger, ZFA, COVID-19, Hematology, Progression-free survival, ZF, Cancer, Death, R, AML, Research and development, MNK, Rated R, Cell, Society, Azacitidine, Pharmaceutical industry, Vaccine, Cryptocurrency, Genetics, Northwestern University, Medicine, NSCLC

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  • These results, if positive, would enable activities, including interactions with regulatory agencies, intended to support initiation of a Phase 3 registrational trial.
  • Research and Development (R&D) Expenses: R&D expenses were $5.4 million for the quarter ended September 30, 2023, compared to $6.6 million for the same quarter of 2022.
  • Other Income (Expense): Other expense was $0.4 million for the quarter ended September 30, 2023, compared to $0.3 million for the same quarter of 2022.

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
Research and development, Therapy, Insulin, Expense, Administration, VTV, G&A, General Administration of Customs, R, Receptor (biochemistry), Pharmaceutical industry

HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments.

Key Points: 
  • HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments.
  • Cash Position: The Company’s cash position as of September 30, 2023 was $8.2 million compared to $12.1 million as of December 31, 2022.
  • Net Loss: Net loss attributable to vTv shareholders for the three months ended September 30, 2023 was $6.7 million or $0.08 per basic share.
  • Net loss attributable to vTv shareholders for the comparable period a year ago was $4.3 million or $0.05 per basic share.